-
-
12-lead ECG obtained from a 50-year old African American man with hypertension and chest pain.
-
FDA warnings for existing drugs dominate pharmaceutical news this month.
-
Serum analysis of 45 subjects for antibodies and humoral immunity over a median of 15 years showed antiviral responses ranging from 11-19 years for tetanus-diphtheria, 50 years for varicella-zoster, and up to 200 years for measles and mumps.
-
The FDA has approved a non-halogenated nasal steroid for use in pediatric patients aged 6 to 12 years and adults. Ciclesonide is a prodrug that was previously approved for adults and adolescents but was not marketed. It's to be marketed by Nycomed US Inc. as Omnaris.
-
-
This randomized, double-blind, placebo-controlled trial demonstrates that administration of erythropoietin once a week for three weeks does not reduce the incidence of red blood cell transfusion in a mixed population of critically ill patients but is associated with an increased incidence of thrombotic events and a possible decrease in mortality in trauma patients.
-
Weight gain has long been used as a marker of fluid retention in heart failure patients. It is a cheap, simple test that can be performed daily in patients' homes.
-
Two hundred eighty-eight patients hospitalized with severe community-acquired pneumonia (CAP) were followed for 28 days in a prospective multicenter study.
-
